Skip to main content
Fig. 4 | Journal of Neuroinflammation

Fig. 4

From: Chronic administration of AMD3100 increases survival and alleviates pathology in SOD1G93A mice model of ALS

Fig. 4

AMD3100 administration significantly extended 50 days old SOD1G93A mice survival and delayed the disease onset. a Survival of mice treated with AMD3100 (n = 22) and PBS (n = 13) was defined as the point at which animals could not right themselves within 30 s after being placed on their side. Mantel-Cox test; p < 0.0001. b Median survival of mice demonstrates 13 days increase in lifespan. c Maximum survival of mice. d Disease onset was determined as the time animals reached their maximum bodyweight. Mantel-Cox test; p = 0.0036 e Weight change monitored weekly. f Motor function assessed weekly by Rotarod test. Results are mean ± S.E.M., *p < 0.05, **p < 0.01

Back to article page